Enjaymo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limited treatment options for cad, rising diagnosis of rare autoimmune disorders, success of complement inhibitors, increasing orphan drug approvals, growing specialty care centers.

The growth in the forecast period can be attributed to expansion of complement inhibitor pipelines, increasing awareness of rare hemolytic diseases, improved diagnostic capabilities, supportive orphan drug incentives, growth in specialty biologic adoption. Major trends in the forecast period include complement pathway targeted therapies, growth in rare autoimmune disease treatments, shift toward precision immunology, reduction in transfusion dependent therapies, expansion of orphan drug development.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the enjaymo market in the coming years. Autoimmune disorders are a group of conditions in which the immune system, which normally protects the body against harmful invaders like bacteria and viruses, mistakenly attacks healthy tissues and organs. The rise in these disorders is attributed to factors such as improved diagnostics, environmental changes, dietary shifts, sedentary lifestyles, chronic stress, and the hygiene hypothesis affecting immune regulation. Enjaymo, a monoclonal antibody therapy, helps patients by targeting and inhibiting the complement system, specifically C1s, preventing the immune response that destroys red blood cells. This provides significant relief from hemolytic anemia associated with conditions such as cold agglutinin disease and other autoimmune hemolytic disorders. For example, in February 2024, Clinical Trials Arena, a UK-based clinical trials and pharmaceutical development platform, projected that rheumatoid arthritis (RA) cases worldwide are expected to rise sharply, with prevalence increasing by 80.2% and affecting nearly 1% of the global population by 2050. Therefore, the rising prevalence of autoimmune disorders is supporting the growth of the enjaymo market.

The increasing number of clinical trial approvals is also expected to propel the growth of the enjaymo market. Clinical trial approvals involve regulatory agencies reviewing and granting permission for clinical trials to begin. Growth in approvals is driven by advances in biotechnology, the rise of biologics, increased participation from smaller companies, and streamlined regulatory processes for rare diseases and unmet medical needs. Clinical trial approvals for treatments such as enjaymo involve rigorous evaluation of safety and efficacy, expedited pathways for rare diseases, and post-market monitoring. For example, in July 2024, the American Society of Gene and Cell Therapy (ASGCT), a US-based professional organization, reported that 76 gene therapy trials were initiated in the second quarter of 2024, representing a 25% increase compared to the previous quarter. Therefore, the increasing number of clinical trial approvals is expected to support the growth of the enjaymo market.

A key trend in the enjaymo market is obtaining regulatory approvals to improve treatment accessibility and ensure compliance with global healthcare standards. Regulatory approvals involve official authorization by governmental or regulatory bodies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), allowing a drug to be marketed. For instance, in January 2023, Sanofi S.A., a France-based pharmaceutical company, received FDA approval for Enjaymo (sutimlimab-jome), permitting its use in adults with cold agglutinin disease (CAD) regardless of transfusion history. Enjaymo works by targeting the classical complement pathway, preventing the immune system from attacking red blood cells. The updated formulation also offers a more convenient administration method, reducing infusion time to one hour biweekly. This approval represents a significant advancement in treatment options for CAD patients, enhancing their quality of life.

Major companies operating in the enjaymo market are Recordati Industria Chimica e Farmaceutica S.p.A.

North America was the largest region in the enjaymo market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the enjaymo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the enjaymo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the enjaymo market by increasing costs for biologic manufacturing inputs and temperature controlled logistics. These impacts are most significant for specialty hospitals and hematology clinics in regions reliant on imported rare disease therapies. Higher tariffs may influence treatment pricing and reimbursement discussions. However, tariffs are encouraging regional production and partnerships for orphan drugs. This supports long term availability and supply chain diversification.

The enjaymo market research report is one of a series of new reports that provides enjaymo market statistics, including enjaymo industry global market size, regional shares, competitors with a enjaymo market share, detailed enjaymo market segments, market trends and opportunities, and any further data you may need to thrive in the enjaymo industry. This enjaymo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Enjaymo (sutimlimab) is a complement inhibitor approved for the treatment of cold agglutinin disease (CAD) in adults, a rare autoimmune hemolytic anemia in which the immune system destroys red blood cells at cold temperatures. It works by blocking the C1s protein in the classical complement pathway, preventing red blood cell destruction and reducing the need for blood transfusions.

The primary clinical indications for enjaymo include cold agglutinin disease (CAD), autoimmune hemolytic anemia (AIHA), complement-mediated hemolytic disorders, and off-label or emerging uses. Cold agglutinin disease is a rare autoimmune hemolytic anemia in which the immune system produces cold-reactive autoantibodies called cold agglutinins. The drug belongs to various classes, including monoclonal antibodies, corticosteroids, immunosuppressants, and other biologic therapies, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The enjaymo market consists of sales of products including injection, and drug. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.